Local ablative therapy

PROCEDURE4 trials

Sponsors

Universitaire Ziekenhuizen KU Leuven, Memorial Sloan Kettering Cancer Center, Australasian Gastro-Intestinal Trials Group, Chinese University of Hong Kong

Conditions

Colorectal CancerLung Cancer (NSCLC)Metastatic Non Small Cell Lung CancerMinimal Residual DiseaseNSCLC Stage IVNon Small Cell Lung Cancer MetastaticNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorNon-small Cell Lung Cancer

Phase 2

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT05429320

Memorial Sloan Kettering Cancer CenterMetastatic Non Small Cell Lung Cancer, Minimal Residual Disease, Non-small Cell Lung Cancer +3

Start: 2022-06-15End: 2026-01-28Updated: 2026-02-02

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

RecruitingNCT07379476

Chinese University of Hong KongLung Cancer (NSCLC)

Start: 2026-02-11End: 2030-03-03Target: 64Updated: 2026-02-12

Unknown Phase

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

RecruitingNCT04216121

Universitaire Ziekenhuizen KU LeuvenNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Start: 2021-05-10End: 2025-10-31Target: 39Updated: 2024-07-01

RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Active, not recruitingNCT05862051

Australasian Gastro-Intestinal Trials GroupColorectal Cancer, Oligometastatic Disease

Start: 2021-12-14End: 2027-12-01Updated: 2026-05-08